![Properties of DURO-TAK ® 87-2074, DURO-TAK ® 87-2051, and DURO-TAK ®... | Download Scientific Diagram Properties of DURO-TAK ® 87-2074, DURO-TAK ® 87-2051, and DURO-TAK ®... | Download Scientific Diagram](https://www.researchgate.net/publication/357881136/figure/tbl4/AS:1114689887059970@1642774187203/Properties-of-DURO-TAK-R-87-2074-DURO-TAK-R-87-2051-and-DURO-TAK-R-87-219_Q320.jpg)
Properties of DURO-TAK ® 87-2074, DURO-TAK ® 87-2051, and DURO-TAK ®... | Download Scientific Diagram
![A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory](https://ars.els-cdn.com/content/image/1-s2.0-S0006497118597846-gr1.jpg)
A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory
![Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement | Scientific Reports Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-021-93888-0/MediaObjects/41598_2021_93888_Fig1_HTML.png)